NCT02465502 is a Phase 2 clinical trial of Regorafenib (Stivarga, BAY73-4506) in Colorectal Neoplasms, sponsored by Bayer.

Who is sponsoring NCT02465502?

NCT02465502 is sponsored by Bayer.

What drugs are being tested in NCT02465502?

Interventions in NCT02465502: Regorafenib (Stivarga, BAY73-4506).

What condition does NCT02465502 study?

NCT02465502 studies Colorectal Neoplasms.

Is NCT02465502 still recruiting?

NCT02465502 is currently completed. Last updated 7 November 2018.

Last reviewed 2018-11-07 · How we verify

NCT02465502

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Regorafenib in Subjects With Antiangiogenic-naive and Chemotherapy-refractory Advanced Colorectal Cancer

Completed Phase 2 Last updated 7 November 2018

What this trial tests

Phase 2 trial testing Regorafenib (Stivarga, BAY73-4506) in Colorectal Neoplasms in 59 participants. Completed in 11 December 2017.

Timeline

21 July 2015

Primary endpoint
2 May 2017

11 December 2017

Quick facts

Lead sponsor	Bayer
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	59
Start date	21 July 2015
Primary completion	2 May 2017
Estimated completion	11 December 2017
Sites	1 location across Brazil

Drugs / interventions tested

Regorafenib (Stivarga, BAY73-4506) — full drug profile →

Conditions studied

Colorectal Neoplasms — all drugs for Colorectal Neoplasms →

Sponsor

Bayer — full company profile →

Who can join

18 and older, any sex, with Colorectal Neoplasms. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

To determine the efficacy (as measured by progression-free survival \[PFS\] rate at 8 weeks) of regorafenib in subjects with metastatic colorectal cancer (CRC) whose disease is refractory to standard therapies and who were never exposed to antiangiogenic therapy.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Cancer combination therapies by angiogenesis inhibitors; a comprehensive review.
Ansari MJ, Bokov D, Markov A, Jalil AT, et al · · 2022 · cited 117× · PMID 35392964 · DOI 10.1186/s12964-022-00838-y
Regorafenib in Patients with Antiangiogenic-Naïve and Chemotherapy-Refractory Advanced Colorectal Cancer: Results from a Phase IIb Trial.
Riechelmann RP, Leite LS, Bariani GM, Glasberg J, et al · · 2019 · cited 13× · PMID 31175167 · DOI 10.1634/theoncologist.2019-0067

Verify or expand the search:

Other trials of Regorafenib (Stivarga, BAY73-4506)

Trials testing the same drug.

NCT06137170 — A Real-World Study to Learn More About the Order of Different Treatments and Their Effects in People With Metastatic Col · completed
NCT06321055 — An Observational Study to Learn More About Treatment With Regorafenib in People With Advanced Gastrointestinal Stromal T · completed
NCT06246643 — A Study of Continued Treatment With Regorafenib in Participants With Solid Tumors Who Have Participated in Other Bayer S · Phase 2 · active not recruiting
NCT06029010 — An Observational Study to Learn More About the Long-Term Responses to Treatment With Regorafenib in Patients With Metast · completed
NCT04696055 — Regorafenib Plus Pembrolizumab in Patients With Advanced or Spreading Liver Cancer Who Have Been Previously Treated With · Phase 2 · completed

Other recruiting trials for Colorectal Neoplasms

Currently open trials in the same condition.

NCT06983639 — Randomized Trial Comparing Fecal Testing (FIT) to Colonoscopy for Post-polypectomy Surveillance · NA · recruiting
NCT07222800 — Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult · Phase 3 · recruiting
NCT07239479 — DEXDES Trial: Dexmedetomidine-Desflurane Combination in Laparoscopic Colectomy · NA · recruiting
NCT07262840 — Health Behavior Change in High-Risk Colorectal Cancer Individuals · NA · recruiting
NCT07257653 — The Safety and Efficacy of Cetuximab Beta Plus Fruquintinib With or Without Immune Checkpoint Inhibitorrs in First-line · Phase 2 · recruiting

Other Bayer trials

Trials by the same sponsor.

NCT05900388 — A Study to Observe the Pattern of Use and Safety of Rivaroxaban in Children Under 2 Years Old With Venous Thromboembolis · not yet recruiting
NCT07490431 — An Observational Study to Learn More About How Elinzanetant is Used and How Well it Works for Women With Menopause Sympt · not yet recruiting
NCT05477953 — An Observational Pregnancy Safety Study in Women Who Were Exposed to the Drug Nifurtimox During Pregnancy to Learn About · not yet recruiting
NCT07192952 — A Study to Learn More About How Safe Finerenone is, When it is Taken for a Longer Time With Standard Treatment, in Child · Phase 3 · not yet recruiting
NCT07450599 — A Study to Learn How Well a Combination of Darolutamide and Androgen Deprivation Therapy (ADT) Works as a Treatment Befo · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02465502 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Bayer
Last refreshed: 7 November 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02465502.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing